|
Unten sind die Deals die in den letzten 6 monate abgeschlossen wurden was für die leistung des Managements spricht : Bausch Health acquires U.S. rights for Eton's eye drop ..2019-02-19 https://www.stockwatch.com/News/Item.aspx?bid=Z-C%3aBHC-2719… Bausch Health Companies Inc.'s subsidiary, Bausch + Lomb, has acquired the United States rights to Eton Pharmaceuticals' EM-100, an investigational eye drop, that, if approved, will be the first over-the-counter (OTC) preservative-free formulation eye drop for the treatment of ocular itching associated with allergic conjunctivitis. EM-100 has been submitted to the U.S. Food and Drug Administration (FDA) for review. Eton Pharmaceuticals Announces Licensing of Lamotrigine New Drug Application and Provides Pipeline Update https://ir.etonpharma.com/news-releases/news-release-details… Unique patent-pending formulation of lamotrigine addresses significant unmet need in pediatric epilepsy patients NDA was submitted in May 2019; product launch anticipated in 1H 2020 Lamotrigine market currently exceeds $700 million annually Eton Pharmaceuticals Enters Into License Agreement for Two Branded Hospital Product Candidates https://ir.etonpharma.com/news-releases/news-release-details… ET-202 NDA was submitted in December 2018; PDUFA date expected to be in Q4 2019 ET-203 NDA expected to be submitted by Q3 2019 Eton Pharmaceuticals Announces Licensing of Oral Liquid Product Candidate ET-104 https://ir.etonpharma.com/news-releases/news-release-details… New Drug Application expected to be filed in 2019 |
|
| aus der Diskussion: | ETON (Mkap $133 M) 3x FDA-Entscheide + Multiple NDA-Anträge in kürze |
| Autor (Datum des Eintrages): | Biohero (24.06.19 14:17:41) |
| Beitrag: | 2 von 309 (ID:60877095) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |